Results 201 to 210 of about 29,286 (231)
Some of the next articles are maybe not open access.
BioDrugs, 2010
Dasatinib is approved for the treatment of chronic myeloid leukemia (CML) in patients with resistance or intolerance to imatinib. This article reviews pharmacokinetic, pharmacodynamic, and clinical data on dasatinib, and highlights some of the most important issues that need to be addressed.
CONDORELLI, Fabrizio, GENAZZANI, Armando
openaire +4 more sources
Dasatinib is approved for the treatment of chronic myeloid leukemia (CML) in patients with resistance or intolerance to imatinib. This article reviews pharmacokinetic, pharmacodynamic, and clinical data on dasatinib, and highlights some of the most important issues that need to be addressed.
CONDORELLI, Fabrizio, GENAZZANI, Armando
openaire +4 more sources
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
Circulation, 2012 International audienceBACKGROUND: The French pulmonary hypertension (PH) registry allows the survey of epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have chronic myelogenous leukemia treated with the ...
David Montani +2 more
exaly +2 more sources
Drugs of Today, 2007
Dasatinib is an orally bioavailable potent inhibitor of multiple tyrosine kinases, including ABL and SRC. Preclinical studies have shown dasatinib to be a much more potent inhibitor of BCR-ABL than imatinib is, and to harbor efficacy against nearly all imatinib-resistant BCR-ABL mutants.
openaire +2 more sources
Dasatinib is an orally bioavailable potent inhibitor of multiple tyrosine kinases, including ABL and SRC. Preclinical studies have shown dasatinib to be a much more potent inhibitor of BCR-ABL than imatinib is, and to harbor efficacy against nearly all imatinib-resistant BCR-ABL mutants.
openaire +2 more sources